ArticleHaematologica2024
Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells.
Abstract read
In one paragraph
Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- CAR T-cells in multiple myeloma: the race to the start line.Bone marrow transplantation · 2026Review
- Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?Targeted oncology · 2026Review
- Neurological complications of CAR T cell therapy for cancers.Nature reviews. Neurology · 2025Review
- Noncanonical and mortality-defining toxicities of CAR T cell therapy.Nature medicine · 2025Review
- The synergistic role of viral infection and immune response in the pathogenesis of facial palsy.Journal of neurovirology · 2025Review
- Evolving strategies for addressing CAR T-cell toxicities.Cancer metastasis reviews · 2024Review
- Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells.Blood advances · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Yamini K KathariUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.
Haroon AhmadUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Neurology, University of Maryland School of Medicine, Baltimore, MD.
Michael E KallenDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD.
Rima KokaDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD.
Destiny OmiliUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Thierry IraguhaUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Jean ClementUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.
Lily PhamUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Neurology, University of Maryland School of Medicine, Baltimore, MD.
Mazhar KhalidUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Neurology, University of Maryland School of Medicine, Baltimore, MD.
Xiaoxuan FanUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Microbiology and Immunology, University of Maryland, Baltimore, MD.
Etse GebruUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Patricia LeshoUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Esther ParkUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Nishanthini DishanthanUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Jillian M BakerDepartment of Microbiology and Immunology, University of Maryland, Baltimore, MD.
Kenneth A DietzeDepartment of Microbiology and Immunology, University of Maryland, Baltimore, MD.
Kim G HankeyUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.
Ashraf BadrosUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Jean A YaredUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Saurabh DahiyaUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Stanford University, Stanford, CA.
Nancy M HardyUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Hakan KocogluUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Tim LuetkensUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Microbiology and Immunology, University of Maryland, Baltimore, MD.
Aaron P RapoportUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Djordje AtanackovicUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Transplant and Cellular Therapy Program, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA; Department of Microbiology and Immunology, University of Maryland, Baltimore, MD. datanackovic@som.umaryland.edu.
Funding
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Vu H. Duong · 2008 to 2026
$51.0MSignaling Pathways in Innate ImmunityT32AI095190 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Stefanie N. Vogel · 2012 to 2026
$4.7MNCI NIH HHS P30 CA134274NIAID NIH HHS T32 AI095190
Abstract
PubMed holds no abstract for this paper.
Indexed as
Multiple MyelomaReceptors, Chimeric AntigenB-Cell Maturation AntigenFacial NerveHumansImmunotherapy, AdoptiveParalysisT-LymphocytesB-Cell Maturation AntigenReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.